Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: rising (125), increasing (1000), growing (210), swelling (247), getting bigger (17), getting higher (87)

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

UHS AR 22-23-6

Description: 2022/23 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2022/23 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-22-23-6.pdf

UHS AR 23-24 Final

Description: 2023/24 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2023/24 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-23-24-Final.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Quality account 24-25 final

Description: QUALITY ACCOUNT 2024/25 QUALITY ACCOUNT Contents Part 1: Statement on quality from the chief executive 1.1 Chief executive’s
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/quality-account-24-25-final1.pdf

Ibrutinib-Venetoclax

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia IBRUTINIB-VENETOCLAX Regimen CLL – Ibrutinib & Venetoclax Indication • Ibrutinib plus Venetoclax is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib-Venetoclax-Ver1.1.pdf

O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Regimen (O-CVP) • NHL – O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Indication • Obinutuzumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine.pdf

O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine (O-CHOP) Regimen • NHL – O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-PrednisoloneVincristine Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine.pdf

Bendamustine-Obinutuzumab

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomib (weekly) with daratumumab and dexamethasone Indication • Daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

11 to 20 of 355

Previous 1 2 3 4 5 … Next